We confirmed p16 overexpression in our series of 78 cervical tumors, as extensively described [3,14,16,21], since strong p16 expression is a proven useful surrogate biomarker for tumors with transcriptionally active HR-HPV [5]. Here, CDKN2A is linked to uterine cervix neoplasm.